211 related articles for article (PubMed ID: 32055299)
21. Investigation of the Tissue Distribution and Physiological Roles of Indoleamine 2,3-Dioxygenase-2.
Jusof FF; Bakmiwewa SM; Weiser S; Too LK; Metz R; Prendergast GC; Fraser ST; Hunt NH; Ball HJ
Int J Tryptophan Res; 2017; 10():1178646917735098. PubMed ID: 29051706
[TBL] [Abstract][Full Text] [Related]
22. Identification of a 2-propanol analogue modulating the non-enzymatic function of indoleamine 2,3-dioxygenase 1.
Albini E; Coletti A; Greco F; Pallotta MT; Mondanelli G; Gargaro M; Belladonna ML; Volpi C; Bianchi R; Grohmann U; Macchiarulo A; Orabona C
Biochem Pharmacol; 2018 Dec; 158():286-297. PubMed ID: 30391205
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors.
Mao LF; Wang YW; Zhao J; Xu GQ; Yao XJ; Li YM
Front Pharmacol; 2020; 11():579024. PubMed ID: 33101032
[TBL] [Abstract][Full Text] [Related]
24. Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance.
Vigneron N; van Baren N; Van den Eynde BJ
Oncoimmunology; 2015 May; 4(5):e1003012. PubMed ID: 26155395
[TBL] [Abstract][Full Text] [Related]
25. Indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors activate the aryl hydrocarbon receptor.
Moyer BJ; Rojas IY; Murray IA; Lee S; Hazlett HF; Perdew GH; Tomlinson CR
Toxicol Appl Pharmacol; 2017 May; 323():74-80. PubMed ID: 28336214
[TBL] [Abstract][Full Text] [Related]
26. Tryptophan deficiency induced by indoleamine 2,3-dioxygenase 1 results in glucose transporter 1-dependent promotion of aerobic glycolysis in pancreatic cancer.
Liang H; Zhan J; Chen Y; Xing Z; He ZNT; Liu Y; Li X; Chen Y; Li Z; Kuang C; Yang D; Yang Q
MedComm (2020); 2024 May; 5(5):e555. PubMed ID: 38706741
[TBL] [Abstract][Full Text] [Related]
27. Synthesis and evaluation of oxindoles as promising inhibitors of the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1.
Paul S; Roy A; Deka SJ; Panda S; Srivastava GN; Trivedi V; Manna D
Medchemcomm; 2017 Aug; 8(8):1640-1654. PubMed ID: 30108875
[TBL] [Abstract][Full Text] [Related]
28. Design, synthesis and evaluation of tryptophan analogues as tool compounds to study IDO1 activity.
Cundy NJ; Hare RK; Tang T; Leach AG; Jowitt TA; Qureshi O; Gordon J; Barnes NM; Brady CA; Raven EL; Grainger RS; Butterworth S
RSC Chem Biol; 2021 Dec; 2(6):1651-1660. PubMed ID: 34977580
[TBL] [Abstract][Full Text] [Related]
29. Design and Synthesis of Indoleamine 2,3-Dioxygenase 1 Inhibitors and Evaluation of Their Use as Anti-Tumor Agents.
Wen H; Liu Y; Wang S; Wang T; Zhang G; Chen X; Li Y; Cui H; Lai F; Sheng L
Molecules; 2019 Jun; 24(11):. PubMed ID: 31195673
[TBL] [Abstract][Full Text] [Related]
30. The interplay between indoleamine 2,3-dioxygenase 1 (IDO1) and cyclooxygenase (COX)-2 in chronic inflammation and cancer.
Cesario A; Rocca B; Rutella S
Curr Med Chem; 2011; 18(15):2263-71. PubMed ID: 21517752
[TBL] [Abstract][Full Text] [Related]
31. Identification of selective inhibitors of indoleamine 2,3-dioxygenase 2.
Bakmiwewa SM; Fatokun AA; Tran A; Payne RJ; Hunt NH; Ball HJ
Bioorg Med Chem Lett; 2012 Dec; 22(24):7641-6. PubMed ID: 23122865
[TBL] [Abstract][Full Text] [Related]
32. Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer.
Dewi DL; Mohapatra SR; Blanco Cabañes S; Adam I; Somarribas Patterson LF; Berdel B; Kahloon M; Thürmann L; Loth S; Heilmann K; Weichenhan D; Mücke O; Heiland I; Wimberger P; Kuhlmann JD; Kellner KH; Schott S; Plass C; Platten M; Gerhäuser C; Trump S; Opitz CA
Oncoimmunology; 2017; 6(2):e1274477. PubMed ID: 28344890
[TBL] [Abstract][Full Text] [Related]
33. The absence of indoleamine 2,3-dioxygenase expression protects against NMDA receptor-mediated excitotoxicity in mouse brain.
Mazarei G; Budac DP; Lu G; Lee H; Möller T; Leavitt BR
Exp Neurol; 2013 Nov; 249():144-8. PubMed ID: 23994717
[TBL] [Abstract][Full Text] [Related]
34. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Triplett TA; Garrison KC; Marshall N; Donkor M; Blazeck J; Lamb C; Qerqez A; Dekker JD; Tanno Y; Lu WC; Karamitros CS; Ford K; Tan B; Zhang XM; McGovern K; Coma S; Kumada Y; Yamany MS; Sentandreu E; Fromm G; Tiziani S; Schreiber TH; Manfredi M; Ehrlich LIR; Stone E; Georgiou G
Nat Biotechnol; 2018 Sep; 36(8):758-764. PubMed ID: 30010674
[TBL] [Abstract][Full Text] [Related]
35. Correlation of indoleamine-2,3-dioxigenase 1 inhibitory activity of 4,6-disubstituted indazole derivatives and their heme binding affinity.
Tsujino H; Uno T; Yamashita T; Katsuda M; Takada K; Saiki T; Maeda S; Takagi A; Masuda S; Kawano Y; Meguro K; Akai S
Bioorg Med Chem Lett; 2019 Oct; 29(19):126607. PubMed ID: 31431359
[TBL] [Abstract][Full Text] [Related]
36. Discovery of Novel 1,2,3-triazole Derivatives as IDO1 Inhibitors.
Hou X; Gong X; Mao L; Zhao J; Yang J
Pharmaceuticals (Basel); 2022 Oct; 15(11):. PubMed ID: 36355488
[TBL] [Abstract][Full Text] [Related]
37. High-throughput fluorescence-based screening assays for tryptophan-catabolizing enzymes.
Seegers N; van Doornmalen AM; Uitdehaag JC; de Man J; Buijsman RC; Zaman GJ
J Biomol Screen; 2014 Oct; 19(9):1266-74. PubMed ID: 24870017
[TBL] [Abstract][Full Text] [Related]
38. Inhibition Mechanisms of Indoleamine 2,3-Dioxygenase 1 (IDO1).
Röhrig UF; Reynaud A; Majjigapu SR; Vogel P; Pojer F; Zoete V
J Med Chem; 2019 Oct; 62(19):8784-8795. PubMed ID: 31525930
[TBL] [Abstract][Full Text] [Related]
39. Galectin 3 protects from cisplatin-induced acute kidney injury by promoting TLR-2-dependent activation of IDO1/Kynurenine pathway in renal DCs.
Volarevic V; Markovic BS; Jankovic MG; Djokovic B; Jovicic N; Harrell CR; Fellabaum C; Djonov V; Arsenijevic N; Lukic ML
Theranostics; 2019; 9(20):5976-6001. PubMed ID: 31534532
[TBL] [Abstract][Full Text] [Related]
40. 1,2,3-Triazoles as inhibitors of indoleamine 2,3-dioxygenase 2 (IDO2).
Röhrig UF; Majjigapu SR; Caldelari D; Dilek N; Reichenbach P; Ascencao K; Irving M; Coukos G; Vogel P; Zoete V; Michielin O
Bioorg Med Chem Lett; 2016 Sep; 26(17):4330-3. PubMed ID: 27469130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
